Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Withdrawn × Paraganglioma × Clear all

Phase

Phase 2 3 Phase 1/2 1 Phase 1 1

Status

Recruiting 3 Completed 2 Withdrawn 1 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1 CNS 1

Conditions

Neoplasms 57 Breast Neoplasms 52 Carcinoma, Non-Small-Cell Lung 40 Leukemia, Myeloid, Acute 39 Lymphoma 34 Pancreatic Neoplasms 30 Leukemia, Lymphocytic, Chronic, B-Cell 30 Leukemia 30 Neoplasm Metastasis 27 Precursor Cell Lymphoblastic Leukemia-Lymphoma 25 Ovarian Neoplasms 25 Lymphoma, Non-Hodgkin 25 Multiple Myeloma 24 Lung Neoplasms 23 Recurrence 22 Melanoma 22 Lymphoma, Large B-Cell, Diffuse 21 Prostatic Neoplasms 20 Glioblastoma 20 Brain Neoplasms 19 Colorectal Neoplasms 18 Lymphoma, Follicular 17 Squamous Cell Carcinoma of Head and Neck 16 Sarcoma 16 Lymphoma, Mantle-Cell 14 Lymphoma, B-Cell 14 Myelodysplastic Syndromes 13 Urinary Bladder Neoplasms 12 Lymphoma, B-Cell, Marginal Zone 12 Glioma 12

Interventions

vandetanib 1 3-Iodobenzylguanidine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01941849 2015-12-21

VIBRaNT

University College, London

Phase 1 Withdrawn

CNSEndocrineNET

Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡